Poulikos Poulikakos, Yogindra Persaud, M. Janakiraman, X. Kong, Charles Ng, G. Moriceau, Hubing Shi, M. Atefi, B. Titz, M. Gabay, M. Salton, K. Dahlman, M. Tadi, J. Wargo, K. Flaherty, M. Kelley, T. Misteli, P. Chapman, J. Sosman, T. Graeber, A. Ribas, R. Lo, N. Rosen, D. Solit (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 480
Eran Hodis, I. Watson, G. Kryukov, S. Arold, M. Imieliński, Jean-Philippe Theurillat, E. Nickerson, D. Auclair, Liren Li, C. Place, D. Dicara, A. Ramos, M. Lawrence, K. Cibulskis, A. Sivachenko, Douglas Voet, G. Saksena, Nicolas Stransky, R. Onofrio, W. Winckler, K. Ardlie, N. Wagle, J. Wargo, K. Chong, D. Morton, K. Stemke‐Hale, Guo Chen, M. Noble, M. Meyerson, J. Ladbury, M. Davies, J. Gershenwald, S. Wagner, D. Hoon, D. Schadendorf, E. Lander, S. Gabriel, G. Getz, L. Garraway, L. Chin (2012)
A Landscape of Driver Mutations in MelanomaCell, 150
K. Cibulskis, A. McKenna, T. Fennell, E. Banks, M. DePristo, G. Getz (2011)
ContEst: estimating cross-contamination of human samples in next-generation sequencing dataBioinformatics, 27 18
V. Leshchenko, Pei-Yu Kuo, R. Shaknovich, David Yang, Tobias Gellen, A. Petrich, Yiting Yu, Y. Remache, M. Weniger, S. Rafiq, K. Suh, A. Goy, W. Wilson, A. Verma, I. Braunschweig, N. Muthusamy, B. Kahl, J. Byrd, A. Wiestner, A. Melnick, S. Parekh (2010)
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.Blood, 116 7
REFERENCES
K. Trunzer, A. Pavlick, L. Schuchter, R. Gonzalez, G. McArthur, Thomas Hutson, S. Moschos, K. Flaherty, Kevin Kim, J. Weber, P. Hersey, G. Long, D. Lawrence, P. Ott, R. Amaravadi, K. Lewis, I. Puzanov, R. Lo, A. Koehler, M. Kockx, O. Spleiss, Annette Schell-Steven, H. Gilbert, L. Cockey, G. Bollag, Richard Lee, A. Joe, J. Sosman, A. Ribas (2013)
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 14
P. Lito, C. Pratilas, E. Joseph, M. Tadi, Ensar Halilovic, Matthew Zubrowski, A. Huang, W. Wong, M. Callahan, T. Merghoub, J. Wolchok, E. Stanchina, S. Chandarlapaty, Poulikos Poulikakos, J. Fagin, N. Rosen (2012)
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.Cancer cell, 22 5
Michael Reich, T. Liefeld, Joshua Gould, Jim Lerner, P. Tamayo, J. Mesirov (2006)
GenePattern 2.0Nature Genetics, 38
R. Nazarian, Hubing Shi, Qi Wang, X. Kong, R. Koya, Hane Lee, Zugen Chen, Mi-Kyung Lee, N. Attar, H. Sazegar, T. Chodon, S. Nelson, G. McArthur, J. Sosman, A. Ribas, R. Lo (2010)
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 468
I. Yeh (2012)
Faculty Opinions recommendation of Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Garraway Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc
F. Xing, Yogindra Persaud, C. Pratilas, B. Taylor, M. Janakiraman, Q. She, H. Gallardo, Cailian Liu, T. Merghoub, B. Hefter, Igor Dolgalev, A. Viale, A. Heguy, E. Stanchina, D. Cobrinik, G. Bollag, J. Wolchok, A. Houghton, D. Solit (2012)
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAFOncogene, 31
P50 CA 93683; to L.A. Garraway), National Human Genome Research Institute (Award #5U54HG003067-11 Gabriel), the Melanoma Research Alliance (to L.A. Garraway), the Dr
J. Sosman, Kevin Kim, L. Schuchter, R. Gonzalez, A. Pavlick, J. Weber, G. McArthur, Thomas Hutson, S. Moschos, K. Flaherty, P. Hersey, R. Kefford, D. Lawrence, I. Puzanov, K. Lewis, R. Amaravadi, B. Chmielowski, H. Lawrence, Y. Shyr, Fei Ye, Jiang Li, K. Nolop, Richard Lee, A. Joe, A. Ribas (2012)
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.The New England journal of medicine, 366 8
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature, 487
(2013)
American Association for Cancer Research. cancerdiscovery.aacrjournals.org Downloaded from Published OnlineFirst November
M. Berger, Eran Hodis, T. Heffernan, Y. Deribe, M. Lawrence, A. Protopopov, E. Ivanova, I. Watson, E. Nickerson, P. Ghosh, Hailei Zhang, Rhamy Zeid, X. Ren, K. Cibulskis, A. Sivachenko, N. Wagle, A. Sucker, C. Sougnez, R. Onofrio, L. Ambrogio, D. Auclair, T. Fennell, S. Carter, Y. Drier, P. Stojanov, Meredith Singer, Douglas Voet, R. Jing, G. Saksena, J. Barretina, A. Ramos, Trevor Pugh, Nicolas Stransky, Melissa Parkin, W. Winckler, Scott Mahan, K. Ardlie, J. Baldwin, J. Wargo, D. Schadendorf, M. Meyerson, S. Gabriel, T. Golub, S. Wagner, E. Lander, G. Getz, L. Chin, L. Garraway (2012)
Melanoma genome sequencing reveals frequent PREX2 mutationsNature, 485
Suzanne Schubbert, M. Zenker, Sara Rowe, Silke Böll, C. Klein, G. Bollag, I. Burgt, L. Musante, V. Kalscheuer, L. Wehner, Hoa Nguyen, B. West, Kam Zhang, E. Sistermans, A. Rauch, C. Niemeyer, K. Shannon, C. Kratz (2006)
Germline KRAS mutations cause Noonan syndromeNature Genetics, 38
Cory Johannessen, L. Johnson, F. Piccioni, A. Townes, Dennie Frederick, M. Donahue, Rajiv Narayan, K. Flaherty, J. Wargo, D. Root, L. Garraway (2013)
A melanocyte lineage program confers resistance to MAP kinase pathway inhibitionNature, 504
K. Hoeflich, S. Herter, Janet Tien, L. Wong, L. Berry, J. Chan, Carol O'brien, Z. Modrušan, S. Seshagiri, M. Lackner, H. Stern, E. Choo, Lesley Murray, L. Friedman, M. Belvin (2009)
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.Cancer research, 69 7
M. Girotti, M. Pedersen, B. Sanchez-Laorden, A. Virós, S. Turajlic, D. Niculescu-Duvaz, A. Zambon, J. Sinclair, A. Hayes, M. Gore, P. Lorigan, C. Springer, J. Larkin, C. Jørgensen, R. Marais (2013)
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.Cancer discovery, 3 2
K. Nathanson, Anne-Marie Martin, B. Wubbenhorst, J. Greshock, R. Letrero, K. D’Andrea, S. O'Day, J. Infante, G. Falchook, H. Arkenau, M. Millward, M. Brown, A. Pavlick, M. Davies, B. Ma, R. Gagnon, M. Curtis, P. Lebowitz, R. Kefford, G. Long (2013)
Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)Clinical Cancer Research, 19
Wuguo Deng, Y. Gopal, A. Scott, Guo Chen, S. Woodman, Michael Davies (2012)
Role and therapeutic potential of PI3K‐mTOR signaling in de novo resistance to BRAF inhibitionPigment Cell & Melanoma Research, 25
Sheila Fisher, Andrew Barry, Justin Abreu, Brian Minie, Jillian Nolan, T. Delorey, Geneva Young, Timothy Fennell, Alexander Allen, L. Ambrogio, Aaron Berlin, Brendan Blumenstiel, K. Cibulskis, Dennis Friedrich, Ryan Johnson, F. Juhn, Brian Reilly, Ramy Shammas, John Stalker, S. Sykes, Jon Thompson, John Walsh, Andrew Zimmer, Zac Zwirko, S. Gabriel, R. Nicol, C. Nusbaum (2011)
A scalable, fully automated process for construction of sequence-ready human exome targeted capture librariesGenome Biology, 12
S. Whittaker, Jean-Philippe Theurillat, E. Allen, N. Wagle, Jessica Hsiao, G. Cowley, D. Schadendorf, D. Root, L. Garraway (2013)
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.Cancer discovery, 3 3
Thoraia Shinawi, Victoria Hill, D. Krex, G. Schackert, D. Gentle, M. Morris, Wenbin Wei, G. Cruickshank, E. Maher, F. Latif (2013)
DNA methylation profiles of long- and short-term glioblastoma survivorsEpigenetics, 8
M. Krauthammer, Y. Kong, B. Ha, Perry Evans, Antonella Bacchiocchi, Jamie McCusker, E. Cheng, Matthew Davis, Gerald Goh, Murim Choi, S. Ariyan, D. Narayan, K. Dutton-Regester, A. Capatana, Edna Holman, M. Bosenberg, M. Sznol, H. Kluger, D. Brash, D. Stern, M. Materin, R. Lo, S. Mane, Shuangge Ma, K. Kidd, N. Hayward, R. Lifton, J. Schlessinger, T. Boggon, R. Halaban (2012)
Exome sequencing identifies recurrent somatic RAC1 mutations in melanomaNature genetics, 44
N. Wagle, E. Allen, D. Treacy, Dennie Frederick, Z. Cooper, A. Taylor-Weiner, Mara Rosenberg, E. Goetz, R. Sullivan, Deborah Farlow, Dennis Friedrich, K. Anderka, Danielle Perrin, Cory Johannessen, A. McKenna, K. Cibulskis, G. Kryukov, Eran Hodis, D. Lawrence, Sheila Fisher, G. Getz, S. Gabriel, S. Carter, K. Flaherty, J. Wargo, L. Garraway (2014)
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.Cancer discovery, 4 1
R. Kefford, W. Miller, D. Tan, R. Sullivan, G. Long, R. Dienstmann, W. Tai, K. Flaherty, S. Stutvoet, K. Schumacher, Simon Wandel, L. Parseval, J. Tabernero (2013)
Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors.Journal of Clinical Oncology, 31
J. Greger, S. Eastman, V. Zhang, Maureen Bleam, Ashley Hughes, Kimberly Smitheman, S. Dickerson, S. Laquerre, Li Liu, T. Gilmer (2012)
Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK MutationsMolecular Cancer Therapeutics, 11
F. Janku, J. Wheler, A. Naing, G. Falchook, David Hong, Vanda Stepanek, S. Fu, S. Piha-Paul, J. Lee, R. Luthra, A. Tsimberidou, R. Kurzrock (2013)
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.Cancer research, 73 1
L. Garraway, E. Lander (2013)
Lessons from the Cancer GenomeCell, 153
Hubing Shi, G. Moriceau, X. Kong, R. Koya, R. Nazarian, G. Pupo, Antonella Bacchiocchi, K. Dahlman, B. Chmielowski, J. Sosman, R. Halaban, R. Kefford, G. Long, A. Ribas, R. Lo (2012)
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.Cancer discovery, 2 5
A. Olshen, E. Venkatraman, R. Lucito, M. Wigler (2004)
Circular binary segmentation for the analysis of array-based DNA copy number data.Biostatistics, 5 4
K. Hoeflich, M. Merchant, C. Orr, J. Chan, Doug Otter, L. Berry, I. Kasman, H. Koeppen, K. Rice, Nai-Ying Yang, S. Engst, S. Johnston, L. Friedman, M. Belvin (2012)
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.Cancer research, 72 1
I. Rodríguez-Escudero, María Oliver, A. Andres-Pons, M. Molina, V. Cid, R. Pulido (2011)
A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.Human molecular genetics, 20 21
K. Cibulskis, Mike Lawrence, S. Carter, A. Sivachenko, David Jaffe, C. Sougnez, S. Gabriel, Matthew Meyerson, Eric Lander, G. Getz (2013)
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samplesNature biotechnology, 31
Maura Costello, Trevor Pugh, T. Fennell, C. Stewart, Lee Lichtenstein, J. Meldrim, Jennifer Fostel, Dennis Friedrich, Danielle Perrin, Danielle Dionne, Sharon Kim, S. Gabriel, E. Lander, Sheila Fisher, G. Getz (2013)
Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparationNucleic Acids Research, 41
François Spitz, Federico Gonzalez, C. Peichel, Thomas Vogt, Denis Duboule, J. Zákány (2001)
Large scale transgenic and cluster deletion analysis of the HoxD complex separate an ancestral regulatory module from evolutionary innovations.Genes & development, 15 17
Kim Paraiso, Y. Xiang, V. Rebecca, Ethan Abel, Y. Chen, A. Munko, Elizabeth Wood, Inna Fedorenko, V. Sondak, A. Anderson, A. Ribas, M. Palma, K. Nathanson, J. Koomen, J. Messina, K. Smalley (2011)
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.Cancer research, 71 7
Vidhu Sharma, Lisa Young, Miguel Cavadas, Kate Owen, Elizabeth Errington (2016)
Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivationeLife, 5
(2006)
Nat Genet
L. Garraway, H. Widlund, M. Rubin, G. Getz, Aaron Berger, Sridhar Ramaswamy, R. Beroukhim, D. Milner, S. Granter, Jinyan Du, Charles Lee, S. Wagner, Cheng Li, T. Golub, D. Rimm, M. Meyerson, D. Fisher, W. Sellers (2005)
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanomaNature, 436
P. Chapman, A. Hauschild, C. Robert, J. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbé, T. Jouary, D. Schadendorf, A. Ribas, S. O'Day, J. Sosman, J. Kirkwood, A. Eggermont, B. Dréno, K. Nolop, Jiang Li, B. Nelson, J. Hou, Richard Lee, K. Flaherty, G. McArthur (2011)
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.The New England journal of medicine, 364 26
A. Hauschild, J. Grob, L. Demidov, T. Jouary, R. Gutzmer, M. Millward, P. Rutkowski, C. Blank, W. Miller, E. Kaempgen, S. Martı́n-Algarra, B. Karaszewska, C. Mauch, V. Chiarion-Sileni, Anne-Marie Martin, S. Swann, P. Haney, B. Mirakhur, Mary Guckert, V. Goodman, P. Chapman (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 380
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 468
Hubing Shi, G. Moriceau, X. Kong, Mi-Kyung Lee, Hane Lee, R. Koya, Charles Ng, T. Chodon, R. Scolyer, K. Dahlman, J. Sosman, R. Kefford, G. Long, S. Nelson, A. Ribas, R. Lo (2012)
Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistanceNature communications, 3
T. Wilson, J. Fridlyand, Yibing Yan, E. Penuel, L. Burton, E. Chan, Jing Peng, Eva Lin, Yulei Wang, J. Sosman, A. Ribas, Jiang Li, John Moffat, D. Sutherlin, H. Koeppen, M. Merchant, R. Neve, J. Settleman (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsNature, 487
Shuang-Yin Han, Hideaki Kato, S. Kato, Takao Suzuki, Hiroyuki Shibata, Seiichi Ishii, Kenichi Shiiba, Seiki Matsuno, Ryunosuke Kanamaru, Chikashi Ishioka (2000)
Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.Cancer research, 60 12
Genetic Resistance Mechanisms to RAF Inhibition in Melanoma RESEARCH ARTICLE
T. Chou, P. Talalay (1984)
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.Advances in enzyme regulation, 22
K. Flaherty, J. Infante, A. Daud, R. Gonzalez, R. Kefford, J. Sosman, O. Hamid, L. Schuchter, J. Cebon, N. Ibrahim, R. Kudchadkar, H. Burris, G. Falchook, A. Algazi, K. Lewis, G. Long, I. Puzanov, P. Lebowitz, A. Singh, S. Little, P. Sun, A. Allred, D. Ouellet, Kevin Kim, K. Patel, J. Weber (2012)
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.The New England journal of medicine, 367 18
M. Krauthammer, Y. Kong, B. Ha, Perry Evans, Antonella Bacchiocchi, Jamie McCusker, E. Cheng, Matthew Davis, Gerald Goh, Murim Choi, S. Ariyan, D. Narayan, K. Dutton-Regester, A. Capatana, Edna Holman, M. Bosenberg, M. Sznol, H. Kluger, D. Brash, D. Stern, M. Materin, R. Lo, S. Mane, Shuangge Ma, K. Kidd, N. Hayward, R. Lifton, J. Schlessinger, T. Boggon, R. Halaban (2016)
Exome sequencing identifies recurrent somatic RAC 1 mutations in melanoma
B. Vogelstein, N. Papadopoulos, V. Velculescu, Shibin Zhou, L. Diaz, K. Kinzler (2013)
Cancer Genome LandscapesScience, 339
Y. Gopal, W. Deng, S. Woodman, K. Komurov, Prahlad Ram, Paul Smith, M. Davies (2010)
Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.Cancer research, 70 21
N. Wagle, Caroline Emery, M. Berger, Matthew Davis, Allison Sawyer, Panisa Pochanard, Sarah Kehoe, Cory Johannessen, L. Macconaill, W. Hahn, M. Meyerson, L. Garraway (2011)
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 22
M. Thakur, Fernando Salangsang, Allison Landman, W. Sellers, N. Pryer, M. Levesque, R. Dummer, M. McMahon, D. Stuart (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistanceNature, 494
Federica Catalanotti, Gloria Reyes, Veronika Jesenberger, G. Galabova-Kovacs, R. Simoes, O. Carugo, M. Baccarini (2009)
A Mek1–Mek2 heterodimer determines the strength and duration of the Erk signalNature Structural &Molecular Biology, 16
N. Kondo, T. Toyama, H. Sugiura, Y. Fujii, H. Yamashita (2009)
miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.Cancer research, 68 13
J. Villanueva, A. Vultur, John Lee, R. Somasundaram, M. Fukunaga-Kalabis, Angela Cipolla, B. Wubbenhorst, Xiaowei Xu, P. Gimotty, D. Kee, A. Santiago-Walker, R. Letrero, K. D’Andrea, A. Pushparajan, James Hayden, K. Brown, S. Laquerre, G. McArthur, J. Sosman, K. Nathanson, M. Herlyn (2010)
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.Cancer cell, 18 6
E. Morris, S. Jha, C. Restaino, P. Dayananth, Hugh Zhu, A. Cooper, D. Carr, Yongi Deng, Weihong Jin, Stuart Black, B. Long, Jenny Liu, Edward Dinunzio, W. Windsor, Rumin Zhang, Shuxia Zhao, M. Angagaw, E. Pinheiro, J. Desai, L. Xiao, G. Shipps, A. Hruza, James Wang, J. Kelly, S. Paliwal, Xiaolei Gao, B. Babu, Liang Zhu, Pierre Daublain, Ling Zhang, B. Lutterbach, Marc Pelletier, U. Philippar, P. Siliphaivanh, D. Witter, P. Kirschmeier, W. Bishop, D. Hicklin, D. Gilliland, L. Jayaraman, L. Zawel, S. Fawell, A. Samatar (2013)
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.Cancer discovery, 3 7
E. Romano, S. Pradervand, Alexandra Paillusson, Johann Weber, K. Harshman, K. Muehlethaler, D. Speiser, S. Peters, D. Rimoldi, O. Michielin (2013)
Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after ProgressionClinical Cancer Research, 19
Cancer Discovery – Unpaywall
Published: Jan 1, 2014
Access the full text.
Sign up today, get DeepDyve free for 14 days.